About Multiple Sclerosis Foundation

Home > Learn About Multiple Sclerosis > News > Study: Two years most effective measure of NEDA status

Study: Two years most effective measure of NEDA status


Researchers at Boston’s Brigham and Women’s Hospital determined that two years may be the best predictive value that no evidence of disease activity (NEDA) status currently offers. NEDA has become a treatment goal but its value as a predictive measure is unknown. The results were part of a seven year study to determine the effectiveness of NEDA.

Investigators looked at 215 patients from the Comprehensive Longitudinal Investigation of Multiple Sclerosis at Brigham and Women’s Hospital study. They measured NEDA status by looking at relapses, disability progression, and yearly magnetic resonance imaging in patients over the course of seven years. They found that 46 percent had NEDA for clinical and MRI measures at 1 year, but only 7.9 percent maintained NEDA status after seven years. NEDA at two years had a positive predictive value of 78.3 percent for no progression.

Authors noted that “NEDA is difficult to sustain long term even with treatment. NEDA status at 2 years may be optimal in terms of prognostic value in the longer term. Our results provide a basis for investigating NEDA as an outcome measure and treatment goal and for evaluating the effect of new MS drugs on NEDA.”

The results were published online in JAMA Neurology.

  Support the MSF
Supporting MSF's programs to help make "a brighter tomorrow" has never been easier.
make a donation 

  Learn About MS
Common symptoms of MS include fatigue, weakness, spasticity, balance problems, bladder and bowel problems, numbness, vision loss, tremors and depression.
learn more 


Unless otherwise specified, all medical content is compiled by MSF staff and reviewed for accuracy by a member of our Medical Advisory Board.

The MSF strives to present clear and unbiased information. This site is partially funded through a grant from Bayer Healthcare, LLC.

© Copyright 2000-2013 Multiple Sclerosis Foundation - All Rights Reserved